⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Pliant Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Pliant Therapeutics
↗South San Francisco, USA
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel integrin-based therapeutics. The company leverages its proprietary drug discovery platform to target integrins, which are key molecular drivers in fibrotic diseases and solid tumors.
Its pipeline includes programs targeting fibrotic tissue-specific inhibition and oncology, with a focus on delivering drug payloads such as siRNAs to specific cell types. The company is publicly traded on the NASDAQ and is headquartered in South San Francisco, California.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2016
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$287.5M
Investors:Novartis
STOCK
Exchange:NASDAQ
Ticker:PLRX
Market Cap:$0.077B
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 1b (PLN-101095)
Modalities:Small molecule, siRNA
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Novartis (Collaboration on PLN-1474 for NASH fibrosis)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Christopher Keenan - Vice President, Investor Relations and Corporate Communications
LINKS
Website:pliantrx.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Pliant Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.